CN1057005C - Application of theaflavine for preparing medicine for treating leukopenia disease - Google Patents
Application of theaflavine for preparing medicine for treating leukopenia disease Download PDFInfo
- Publication number
- CN1057005C CN1057005C CN97116366A CN97116366A CN1057005C CN 1057005 C CN1057005 C CN 1057005C CN 97116366 A CN97116366 A CN 97116366A CN 97116366 A CN97116366 A CN 97116366A CN 1057005 C CN1057005 C CN 1057005C
- Authority
- CN
- China
- Prior art keywords
- tea pigment
- leukopenia
- treatment
- medicine
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 26
- 231100001022 leukopenia Toxicity 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title description 3
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title description 3
- 239000000049 pigment Substances 0.000 claims abstract description 56
- 241001122767 Theaceae Species 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 15
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 230000000610 leukopenic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000014620 theaflavin Nutrition 0.000 description 2
- 229940026509 theaflavin Drugs 0.000 description 2
- 235000008118 thearubigins Nutrition 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 229960003513 batilol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new medicinal application of tea pigment, namely the application of tea pigment in preparing medicine for curing leucopenia.
Description
The present invention relates to the new medicine use of tea pigment, be specifically related to the application of tea pigment in preparation treatment leukopenia disease drug, belong to the field of Chinese medicines.
Tea pigment is the natural plant pigment that extracts from Folium Camelliae sinensis, is a kind of active pigment complex that catechin forms through peroxidating in the tea polyphenols.Tea pigment is made up of theaflavin, thearubigins and abrownin.For the existing bibliographical information of the research of tea pigment.CN1074618A discloses tea pigment and production method thereof.This production process is, Folium Camelliae sinensis is to decoct extracting juice, and alkalization concentrates, and acidify adds alcohol reflux, and alcohol reflux liquid alkalizes and obtains tea pigment crystallization product, through vacuum drying, promptly obtains this tea pigment.Theaflavin, thearubigins and abrownin three have constant ratio in the tea pigment that makes with this method, can be used as medicinal.Medical value report for tea pigment may be summarized to be reduction blood viscosity, blood fat reducing, cholesterol reducing, prevention and treatment cardiovascular disease.But up to the present, the relevant tea pigment of Shang Weijian is used for the treatment of the report of leukopenia.
A kind of new pharmaceutical applications that the purpose of this invention is to provide tea pigment, promptly tea pigment is in the application of the medicine of preparation treatment leukopenia.
Cancer patient put, in the chemotherapy process, leukocyte all has decline in various degree.The hyperthyroidism patient is in therapeutic process, because the side effect of medicine also has leukopenia in various degree.Leukopenia can cause body immunity to descend, the therapy discontinued of having to sometimes, and tea pigment has therapeutical effect preferably for the leukopenia that the treatment a variety of causes causes.
The extracting method of tea pigment of the present invention can extract according to known extraction process, preferably the tea pigment that extracts according to following method:
(1), with Folium Camelliae sinensis by 1: after 15-30 multiple proportions example added water, through once or the decoction extracting juice once, fried liquid is used in the aqueous solution can produce OH
-Ionic chemical compound alkalizes, and regulates pH8-10, at the 1/4-1/10 that heats concentrated this alkaline solution to the original volume amount down less than 70 ℃, gets concentrated solution then; (2) concentrated solution transfers to pH3-6 with acid, and acidifying solution adds ethanol 1-10 volume doubly to be measured, and backflow 0.5-2 hour, gets alcohol reflux liquid; (3) alcohol reflux liquid is used in aqueous solution and can produces OH
-Ionic chemical compound is regulated pH7-10, and post precipitation filters, and gets the tea pigment crystallization, and tea pigment crystallization vacuum drying promptly gets the tea pigment product.
Tea pigment of the present invention is a kind of active constituents of medicine, preparation process according to routine, can be main active constituent with tea pigment, add excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
Because the present invention discloses the pharmacologic action of tea pigment treatment leukopenia first; therefore; tea pigment cooperated separately or with other active constituents or adjuvant make medicament,, all belong to protection scope of the present invention so long as this medicament is used for the treatment of leukopenia.
Tea pigment of the present invention all has the effect of treatment leukopenia when making any dosage form.Any medicament; if contain tea pigment in its component or only prepare patent medicine with the tea pigment single component; on signs such as its packing or description or on other any propaganda materials, need only effect dated or that prompting has the treatment leukopenia, then fall within protection scope of the present invention.
Tea pigment of the present invention is the natural plants Folium Camelliae sinensis that derives from medicine-food two-purpose.Therefore, also tea pigment can be made health food or health care medicine.Health food or health care medicine with tea pigment is made have the effect for the treatment of leukopenia if indicate or point out on signs such as its packing or description, also fall within protection scope of the present invention.
Embodiment 1
Prescription
Tea pigment 125 grams
Medical starch 875 grams
Above-mentioned component is gone into blender, and fully stirring and evenly mixing is encapsulated with capsule machine, and every filling 1 gram makes 1000 of tea pigment capsules, and every capsules contains 125 milligrams of tea pigments.
Embodiment 2
Tea pigment 250 grams
2000 milliliters of distilled water
Stevioside 1 gram
Tea pigment is dissolved in the distilled water, and fully mixing adds stevioside, and stirring and evenly mixing is once more packed in the vial with can packing machine, and every bottled 10 milliliters, sterilization makes the tea pigment oral liquid.
Embodiment 1 tea pigment to put, the observation of chemotherapy patients's leukocyte effect
1 materials and methods
1.1 physical data is divided into two groups at random with 40 routine malignant tumor patients.Experimental group: 20 examples.Wherein the chemotherapy disease is from 12 examples, radiotherapy group 8 examples.Male's 14 examples, women's 6 examples.32～68 years old age (average 45 years old).The sick kind: pneumonopathy 8 examples, the esophageal carcinoma 6 examples, oral cancer 2 examples, ovarian cancer 2 examples, breast carcinoma 2 examples; Matched group 20 examples, chemotherapy patients's 11 examples wherein, radiotherapy group 8 examples.
1.2 method: put, before the chemotherapy, look into patient's leukocyte count as the starting point radix.Put, chemotherapy begins simultaneously experimental group and takes tea pigment, 25mg, every day 3 times, serve on for 4 weeks, matched group is taken batilol, and all the patient all has a blood test routine weekly once, observe leukocytic fall, the decreasing ratio of last leukocyte count and radix is compared with matched group.Relatively adopt the t check between group.
2 results
2.1 two groups of patients are the leukocyte lapse rate weekly: the total rate of descent 22.8% of experimental group, matched group are 52% (table 1) (table is seen the literary composition back)
Table 1 leukocyte lapse rate (%)
Total rate of descent experimental group 6.3 14.0 4.1 22.8 matched groups 33.0 21.0 8.0 52.0 around the 3rd week the of second week
2.2 leukocyte average leukopenia average experimental group is 1.44 * 10 weekly
9/ L (table 2)
Table 2 is leukocyte average (1 * 10 weekly
9/ L)
Total rate of descent experimental group 6.3 5.90 5.67 4.86 1.44 matched groups 75.0 4.98 3.92 3.60 3.90P of the 2nd the 4th week of the 3rd week week of the 1st week＜0.01
3 discuss
Cancer patient put, in the chemotherapy process, its leukocyte all has decline in various degree, especially remakes the patient of chemotherapy and the patient of journey chemotherapy again after the radiotherapy, and is more obvious.The patient who has even have to stop anticancer therapy.Cause treatment of cancer to be subjected to because of disturbing, prolong the course of treatment, and patient's Abwehrkraft des Koepers descends, and the state of an illness can not get good control, becomes one of major obstacle of treatment of cancer.At present, it is more to be used for rising white medicine for the treatment of, but the person of proving effective is few in number.We observe tea pigment chemicotherapy patient leukocyte lapse rate are reduced, make it to maintain on the certain level, with guarantee to put, chemotherapy carries out smoothly, tangible effect is arranged, be that at first person in middle and old age's cancer patient takes, but microcirculation improvement, the cardiovascular and cerebrovascular disease in the prophylactic treatment process; In addition, can pass through microcirculation improvement, fibrinolysis activity, the microthrombus in focus zone is disappeared, blood circulation improves, and the anoxia state in the radiotherapy improves, and radiation sensitivity strengthens.Chemotherapy process, blood drug level improve in the focus zone, thereby strengthen the kill capability of medicine to cancer.
Tea pigment is for the principle of leukogenic effect: (1) microcirculation improvement; (2) fibrinolysis activity, the improvement of blood circulation state helps keeping the stable of organismic internal environment, makes organ-tissue be in optimum state, and body resistance against diseases strengthens.In addition, microcirculation improves and fibrinolysis activity, has improved the leukocytic environment of an activation and idiotrophic state, has reduced injury of blood cell and dead chance, prolongs the survival period of leukocyte under morbid state; Hemopoietic organ and function of organization obtain increasing, and strengthen and resist the ability of damaging due to the extraneous factor, thereby make leukopenia slower.
In a word, tea pigment is used for that cancer patient is put, chemotherapy process, and certain propagation or Stabilization are played in leukocytic minimizing.
The observation of embodiment 2 tea pigments dialogue impact cell in the hyperthyroidism treatment
We add 30 volunteers in the hyperthyroidism disease Drug therapy year February in July, 1996-1997 and have used the tea pigment treatment, observe its influence to blood leukocytes.To among the 96 year first half of the year hyperthyroidism treatment patient be that preface does not add with the leucocyte increasing agent case history when having selected 30 example treatments and contrasts simultaneously with time.
1 materials and methods
1.1 physical data 30 examples are the inpatient all, wherein male 9 examples, women 21 examples.Age 15-48 year; With above enlargement person's 19 examples of thyroid III degree, the I degree is following or do not have enlargement 11 examples; Accompany obvious expophthalmos person 12 examples, hyperthyroidism crisis 2 examples, first danger 3 examples in early stage; Be and make a definite diagnosis treatment for the first time.Numeration of leukocyte is all 4 * 10
3More than/the L, the anti-first of beginning medicine adds the tea pigment treatment simultaneously.
1.2 the anti-first medicine of medicine and method methimazole is produced by Beijing, Beijing pharmaceutical factory, authentication code: the accurate word (1996) of medicine is defended No. 139039 in the capital, every 5mg, and consumption 30-45mg/ day, divide and take for three times, this organizes 12 examples, matched group 10 examples.Or use the propylthiouracil sheet to produce towards brightness pharmaceutical factory by The 2nd Army Medical College, and authentication code: the accurate word (1995) of medicine is defended No. 045007 in Shanghai, every 50mg, and consumption 150-300mg/ day, divide clothes three times, all add and use propranolol 10mg 3/ day.And 2 of vitamin B complex tablets 3/ day.Observation group's 30 examples add with tea pigment provides lot number by the green pharmaceutical Co. Ltd in Chinese-foreign joint Jiangxi: medicine standard (1995) 139-1 number defended in Jiangxi, and every capsules contains tea pigment 125mg, consumption 250mg3/ day, no longer adds and uses other leucocyte increasing agent.30 days is a course of treatment, the omnidistance back check leukocyte that finishes.
The result
Leukopenia is 4 * 10 in observation group's 30 examples
9Following person's 5 examples of/L account for 16.6, numeration of leukocyte 3.0-3.8 * 10
9/ L, average 3.6 * 10
9/ L, none example is stopped anti-first medicine, and in observing in the later stage, leukocyte has the trend that rises in various degree.
Leukopenia is 4 * 10 in matched group 30 examples
9Following person's 14 examples of/L account for 46.6%, and numeration of leukocyte is in 2.2-3.4 * 10
9Between/the L, average 2.8 * 10
9/ L adds to have used shengbai drug greatly, and 5 routine patients are forced to stop anti-first treatment because of leukocyte is low excessively.(seeing Table 1)
The observation situation of table 1 tea pigment dialogue impact cell
Example number leukopenia stops treatment
The white C average (* 10 of N %
9/ L) 30 5 16.6 2.0-3.8,0 matched group, 30 14 46.6 2.2-3.4,53 discussion are organized in the N treatment
The hyperthyroidism sickness rate is higher, and the main method of hyperthyroidism treatment is a Drug therapy.Treatment time is long, generally the several months to the several years, part patient need take medicine throughout one's life.The topmost side effect of anti-first medicine is to cause leukopenia, its incidence rate height, and some adds uses conventional leucocyte increasing agent, and effect is still not remarkable, is forced to drug withdrawal, and influences normally carrying out of hyperthyroidism treatment.We can obviously reduce leukopenic generation according to tea pigment in the chemotherapy of tumors process, add in the process of anti-first treatment and use tea pigment, observe leukocytic influence, found that this medicine can obviously reduce the amplitude of leukopenic incidence rate and minimizing.Its action principle and tea pigment have the ability that stimulates patients undergoing chemotherapy myeloid progenitor propagation, alleviate bone marrow depression, and it is relevant that its generation is increased.
The conclusion tea pigment can reduce the amplitude of leukopenic incidence rate and minimizing in the hyperthyroidism Drug therapy and usefulness significantly, has avoided because of anti-first medicine causes that leukopenia is forced to drug withdrawal, has guaranteed normally carrying out of anti-first treatment.It is valuable adjuvant drug in the anti-first treatment.
Claims (4)
1. the application of tea pigment in preparation treatment leukopenia disease drug.
2. according to the application of claim 1, wherein said leukopenia is meant and puts, chemotherapy patients's leukopenia.
3. application according to claim 1, wherein said leukopenia is meant the leukopenia that occurs in the hyperthyroidism disease human therapy process.
4. application according to claim 1, wherein said medicine is meant health care medicine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116366A CN1057005C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating leukopenia disease |
| PCT/CN1998/000167 WO1999008674A1 (en) | 1997-08-18 | 1998-08-18 | New uses of tea pigment |
| AU87973/98A AU8797398A (en) | 1997-08-18 | 1998-08-18 | New uses of tea pigment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116366A CN1057005C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating leukopenia disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1208637A CN1208637A (en) | 1999-02-24 |
| CN1057005C true CN1057005C (en) | 2000-10-04 |
Family
ID=5173800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97116366A Expired - Fee Related CN1057005C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating leukopenia disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1057005C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074618A (en) * | 1993-01-01 | 1993-07-28 | 南昌洪婺名茶开发公司 | Tea pigment and production method thereof |
-
1997
- 1997-08-18 CN CN97116366A patent/CN1057005C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074618A (en) * | 1993-01-01 | 1993-07-28 | 南昌洪婺名茶开发公司 | Tea pigment and production method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《泰山医学院学报》1997,18(1) 1997.1.31 庄文选等，茶色素配合化疗治疗晚期恶性肿瘤28例 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1208637A (en) | 1999-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN117159620A (en) | Essential oil for weight loss and preparation method and application thereof | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN108056928B (en) | A kind of buccal cavity gel of the rare saponin(e containing Radix Notoginseng and preparation method thereof | |
| CN1057005C (en) | Application of theaflavine for preparing medicine for treating leukopenia disease | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
| CN1078472C (en) | Application of theachrome in preparing medicine for plateau erythrocytosis | |
| CN117599145B (en) | Composition for treating coronary heart disease | |
| CN1064254C (en) | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| RU2821515C1 (en) | Composition based on vegetal raw materials for prevention of inflammatory diseases of kidneys and urinary tract | |
| WO2013008249A2 (en) | Cell regenerating antioxidant | |
| CN100525783C (en) | Application of Rangoon creeper fruit and its extracts in preparation of medicine for promoting lead expelling | |
| WO2025050793A1 (en) | Combination for preventing, ameliorating, and/or treating muscle diseases or muscle disorders | |
| CN1065758C (en) | Application of tea pigments in preparation of medicine for goiter | |
| CN1066339C (en) | Application of theaflavine for prepn. of medicine for treating deafness | |
| CN1065756C (en) | Application of theachrome in preparing medicine for prostatauxe | |
| CN101229227B (en) | Water aqua medicine compounds, preparing method and applications thereof | |
| CN1064253C (en) | Application of tea pigments in preparation of medicine for nephrotic syndrome | |
| CN106491706A (en) | Ginkgo leaf capsule of red sage root | |
| CN105708915B (en) | Application of Wuwei Huanglian Pills in the Preparation of Medicines for the Treatment of Type Ⅱ Diabetes | |
| RU2571287C1 (en) | Agent for endoecological rehabilitation | |
| CN1057007C (en) | Application of theachrome in preparing medicine for pulmonitis | |
| CN112933135A (en) | Composition for treating spleen and stomach weakness and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |